Khoo Michelle, Kelly Patricia A, Lindenfeld JoAnn
University of Colorado Health Sciences Center, 1635 Aurora Court, F749, Aurora, CO 80045, USA.
Curr Cardiol Rep. 2009 May;11(3):175-83. doi: 10.1007/s11886-009-0026-8.
Clinical practice guidelines recommend cardiac resynchronization therapy (CRT) for ambulatory New York Heart Association (NYHA) class IV patients with a QRS duration >or= 120 ms and a left ventricular ejection fraction <or= 35%. Only two prospective, randomized trials have compared outcomes after CRT in NYHA class III and IV patients. CRT improved mortality, exercise capacity, and quality of life in class IV patients, but the 1-year mortality remained high. Patients in these trials were in sinus rhythm at randomization and most patients had a left bundle branch block. Less data are available for NYHA class IV patients with atrial fibrillation, right bundle branch block, and previous ventricular pacing. No prospective randomized data are available for the use of CRT as rescue therapy in inotrope-dependent patients, but several case series have reported promising results. It is likely that "rescue therapy" with CRT will be most beneficial when patients improve enough with CRT to allow reinstitution of angiotensin-converting enzyme inhibitors and beta blockers.
临床实践指南推荐,对于纽约心脏协会(NYHA)心功能IV级、QRS波时限≥120毫秒且左心室射血分数≤35%的非卧床患者,应采用心脏再同步治疗(CRT)。仅有两项前瞻性随机试验比较了NYHA III级和IV级患者接受CRT后的结局。CRT改善了IV级患者的死亡率、运动能力和生活质量,但1年死亡率仍居高不下。这些试验中的患者在随机分组时处于窦性心律,且大多数患者存在左束支传导阻滞。对于合并房颤、右束支传导阻滞及既往有心室起搏的NYHA IV级患者,相关数据较少。目前尚无关于CRT用于依赖血管活性药物患者的挽救治疗的前瞻性随机数据,但多个病例系列报告了有前景的结果。当患者通过CRT改善到足以重新使用血管紧张素转换酶抑制剂和β受体阻滞剂时,CRT“挽救治疗”可能最为有益。